NasdaqGS - Nasdaq Real Time Price USD
Biogen Inc. (BIIB)
216.65 -1.85 (-0.85%)
At close: August 31 at 4:00:01 PM EDT
215.00 -1.65 (-0.76%)
Pre-Market: 6:39:47 AM EDT
Trade Biogen on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreChart Range Bar
Loading chart for BIIB
What's happening with BIIB?
Powered by Yahoo ScoutBiogen's stock has shown a 6.5% increase since its last earnings report, driven by strong growth in new products and raised earnings guidance. Analysts remain cautious due to past revenue declines and competitive pressures, but there are positive signals from upcoming clinical trials and a strengthened pipeline.
Powered by Yahoo Scout
- Previous Close
218.50 - Open
216.47 - Bid 205.67 x 100
- Ask 229.95 x 100
- Day's Range
213.58 - 218.88 - 52 Week Range
133.53 - 222.85 - Volume
807,712 - Avg. Volume
1,127,863 - Market Cap (intraday)
32.011B - Beta (5Y Monthly) 0.16
- PE Ratio (TTM)
38.76 - EPS (TTM)
5.59 - Earnings Date Oct 29, 2026
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
236.22
Recent News
View More
Performance Overview
Trailing total returns as of 8/31/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
BIIB
23.10%
S&P 500 (^GSPC)
12.28%
1-Year Return
BIIB
63.86%
S&P 500 (^GSPC)
18.98%
3-Year Return
BIIB
18.97%
S&P 500 (^GSPC)
70.51%
5-Year Return
BIIB
36.07%
S&P 500 (^GSPC)
69.95%
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
As of 8/27/2026
Market Cap
32.73B
Enterprise Value
39.80B
Trailing P/E
39.34
Forward P/E
18.45
PEG Ratio (5yr expected)
1.56
Price/Sales (ttm)
3.27
Price/Book (mrq)
1.74
Enterprise Value/Revenue
3.97
Enterprise Value/EBITDA
18.60
Financial Highlights
Profitability and Income Statement
Profit Margin
8.32%
Return on Assets (ttm)
5.21%
Return on Equity (ttm)
4.57%
Revenue (ttm)
10.03B
Net Income Avi to Common (ttm)
834.6M
Diluted EPS (ttm)
5.59
Balance Sheet and Cash Flow
Total Cash (mrq)
1.28B
Total Debt/Equity (mrq)
44.33%
Levered Free Cash Flow (ttm)
1.27B
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Mkt Cap undefined -
Industry -
Mkt Cap undefined -
Industry -
Mkt Cap undefined -
Industry -
Mkt Cap undefined -
Industry -
Mkt Cap undefined -
Industry -
Mkt Cap undefined -
Industry -
Mkt Cap undefined -
Industry -
Mkt Cap undefined -
Industry -
Company Insights
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected. Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports
View MoreBiogen Earnings: Growth Portfolio Outpaces Legacy Portfolio Erosion; Guidance Raised
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
RatingPrice TargetBiogen and Ionis: Mixed Phase 2 Data for Alzheimer's Disease Candidate
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
RatingPrice TargetBiogen and Ionis: Mixed Phase 2 Data for Alzheimer's Disease Candidate
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
RatingPrice TargetManagement lowers guidance, near-term upside seems limited
Biogen is a biotech company that develops, manufactures, and sells therapies for treating neurological and neurodegenerative diseases. The company is the market leader in MS drugs and launched the first approved treatments for spinal muscular atrophy and AD. The company also sells products that treat plaque psoriasis, non-Hodgkin's lymphoma, lymphocytic leukemia, and rheumatoid arthritis. Current research continues on MS and has expanded to include neuroimmunology, ophthalmology, lupus, and other neuromuscular and movement disorders. Founded in 1978, the company is located in Cambridge, Massachusetts; employs 7,500 people; and is a component of the S&P 500.
RatingPrice Target